Erasca (ERAS) Profit After Tax (2020 - 2026)
Erasca's (ERAS) quarterly Profit After Tax came in at -$184.8 million in Q1 2026, down 496.68% YoY from $46.6 million in Q1 2025, and down 534.65% on a QoQ basis from -$29.1 million in Q4 2025.
Erasca (ERAS) Profit After Tax (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Profit After Tax data on file, last reported at -$184.8 million in Q1 2026.
- Quarterly Profit After Tax fell 496.68% year-over-year to -$184.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$278.4 million (down 77.31% YoY) and the FY2025 annual result came in at -$124.3 million, up 22.93% from the prior year.
- Profit After Tax declined to -$184.8 million in Q1 2026, from -$29.1 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$29.1 million in Q4 2025 to a low of -$184.8 million in Q1 2026.
- A 5-year average of -$49.3 million and a median of -$33.7 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 77.49% — and 2026, when it sank 496.68%.
- Tracing ERAS's Profit After Tax over 5 years: stood at -$134.0 million in 2022, then soared by 77.49% to -$30.2 million in 2023, then decreased by 11.55% to -$33.7 million in 2024, then climbed by 13.49% to -$29.1 million in 2025, then sank by 534.65% to -$184.8 million in 2026.
- The last three Profit After Tax figures came in at -$184.8 million (Q1 2026), -$29.1 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -44.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.63 Mn |
| Mar 31, 2026 | -184.77 Mn |
| Dec 31, 2025 | -29.11 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -33.65 Mn |
| Sep 30, 2024 | -29.18 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -30.17 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -134.03 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.46 Mn |
| Sep 30, 2021 | -46.07 Mn |